-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Uncategorized
-
In Brief for February 11, 2026
Nogapendekin alfa combination gains accelerated approval in Saudi Arabia for metastatic NSCLC.
-
TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19
By Marina Chiara Garassino, MD, and Leora Horn, MD, MSc, FRCPC Posted: June 9, 2020 Marina Chiara Garassino Leora Horn The new SARS-CoV-2 (COVID-19) virus appeared at the end of December 2019 in Wuhan, China, and soon spread globally. In February 2020, the first cases appeared in Europe, and in…
-
Lung Cancer Considered – Episode XXV – Mar 16, 2020 Dr. Marty Edelman Speaks With IASLC President Dr. Tetsuya Mitsudomi
Posted: April 16, 2020 In this latest episode of Lung Cancer Considered, the official podcast of the IASLC, Dr. Marty Edelman speaks with IASLC President Dr. Tetsuya Mitsudomi. Download the podcast. New episodes of Lung Cancer Considered are released on the first and third Monday of each month.
-
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. Immune checkpoint inhibition is now part of routine care for patients with…
-
JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit
By Hossein Borghaei, DO, MS Posted: August 14, 2019 In 2015, the use of checkpoint inhibitors in the second-line setting for metastatic lung cancer became the standard of care with the approval first of nivolumab followed by pembrolizumab and later atezolizumab. In all randomized trials with these agents, the comparator arm was docetaxel because it represented…
-
c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly
Posted: April 1, 2019 The first in-human study evaluating telisotuzumab vedotin (Teliso-V)—a c-MET antibody–drug conjugate formerly known as ABBV-399— has shown encouraging activity for patients with c-MET–positive NSCLC.1 Teliso-V combines the anti–c-MET monoclonal antibody ABT-700 (telisotuzumab) with monomethyl auristatin E, a cytotoxic antimicrotubule agent. Of the 48 patients enrolled, 35.4% had NSCLC and all were heavily…
-
An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies
Posted: March 1, 2019 Federico Cappuzzo, MD, PhD, has been the director of Medical Oncology at AUSL della Romagna, Ravenna, Italy, since April 2016; in January 2017 he became the director of the Hematology and Oncology Department. The author of more than 200 papers, Dr. Cappuzzo is an extremely active member of the IASLC, having…
-
Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark
Posted: March 1, 2019 On December 6, 2018, the U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with bevacizumab and chemotherapy, specifically paclitaxel and carboplatin, in advanced nonsquamous NSCLC. As part of a larger phase III trial, this combination (PCBA) proved superior to the “standard” combination of bevacizumab/paclitaxel/carboplatin (PCB). In the wild-type population,…
-
The IASLC Fight Against Lung Cancer in Peru and Latin America
By Dr. Luis E. Raez, MD Posted: October 2018 Peru is one of the largest Latin American countries, with a population of approximately 28 million people. Cancer is not yet a leading cause of mortality because of the young median age of the population and other factors like the high prevalence of infectious diseases; in…
-
Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement
Posted: June 2018 Howard A. “Skip” Burris III, MD, is the chief medical officer and president of clinical operations at Sarah Cannon, the Cancer Institute of HCA Healthcare, where he leads clinical, strategic, and drug-development initiatives. Dr. Burris also is an associate with Tennessee Oncology, PLLC. In the interview below, Dr. Burris discusses the “extended…
View ILCN Archives
Provider Resources
Popular Articles